Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Timing of Disease Progression and Impact on Survival in Mantle Cell Lymphoma: A Novel Illness-Death Model Study from the Swedish Mclcomplete Project

Sara Ekberg, Ingrid Glimelius, Alexandra Albertsson-Lindblad, Karin Ekstroem Smedby, Mats Jerkeman, Caroline E Dietrich

Blood (2024) 144 (Supplement 1): 3014.

https://doi.org/10.1182/blood-2024-200664

Published: 2024

Journal Articles

Survival in Mantle Cell Lymphoma Patients with a Second Primary Malignancy

Kossi D Abalo, Trine Trap, Joachim Baech, Sara Ekberg, Simon Pahnke, Alexandra Albertsson-Lindblad, Karin Ekstroem Smedby, Mats Jerkeman, Peter Brown, Thomas Stauffer Larsen, Kirsten Gronbaek, Tarec Christoffer El-Galaly, Ingrid Glimelius

Blood (2024) 144 (Supplement 1): 1638.

https://doi.org/10.1182/blood-2024-206964

Published: 2024

Journal Articles

An International Multicohort Study of Conditional Survival and Cause of Death after Achieving Event-Free Survival at 24 Months in Patients with Mantle Cell Lymphoma

Blood (2023) 142 (Supplement 1): 1656.

https://doi.org/10.1182/blood-2023-182747

Published: 2023

Journal Articles

Sars-Cov-2 Infection Does Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study

Blood (2023) 142 (Supplement 1): 4766.

https://doi.org/10.1182/blood-2023-173078

Published: 2023

Journal Articles

Risk Factors of Smoldering Multiple Myeloma: Results from the Screened Istopmm Study

Blood (2023) 142 (Supplement 1): 3397.

https://doi.org/10.1182/blood-2023-188469

Published: 2023

Journal Articles

Sars-Cov-2 Vaccinations Do Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study

Blood (2022) 140 (Supplement 1): 261–263.

https://doi.org/10.1182/blood-2022-157138

Published: 2022

Journal Articles

Transient M-Proteins: Epidemiology, Causes, and the Impact of Mass Spectrometry: The Istopmm Study

Blood (2022) 140 (Supplement 1): 2338–2340.

https://doi.org/10.1182/blood-2022-164758

Published: 2022

Journal Articles

Late Effects after Treatment in Mantle Cell Lymphoma: No Difference By Intensity of First-Line Regimens with or without Autologous Stem Cell Transplantation

Sara Ekberg, Karin E. Smedby, Alexandra Albertsson-Lindblad, Mats Jerkeman, Caroline Weibull, Ingrid Glimelius

Blood (2021) 138 (Supplement 1): 1344.

https://doi.org/10.1182/blood-2021-145450

Published: 2021

Journal Articles

Idelalisib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: First Results from the Nordic Lymphoma Group NLG-LBC-07 (ILIAD) Phase II Trial

Karin Fjorden, Sara Ekberg, Nevzeta Kuric, Karin Ekstroem Smedby, Ingemar Lagerlöf, MD, Thomas S. Larsen, MD, Judit M. Jørgensen, MD PhD, Peter de Nully Brown, MD PhD, Mats Jerkeman, MD PhD

Blood (2020) 136 (Supplement 1): 33.

https://doi.org/10.1182/blood-2020-133359

Published: 2020

Journal Articles

Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - Data from the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase I Trial: Stopping Treatment in Molecular Remission Is Feasible

Mats Jerkeman, MD PhD, Arne Kolstad, MD PhD, Carsten Utoft Niemann, MD PhD, Kirsten Groenbaek, MD DMSc, Martin Hutchings, MD PhD, Annika Pasanen, MD PhD, Sara Ekberg, Karin Fahl Wader, MD PhD, Ingrid Glimelius, MD PhD

Blood (2020) 136 (Supplement 1): 15.

https://doi.org/10.1182/blood-2020-133273

Published: 2020

Journal Articles

Evaluation of Eligibility for CAR-T Cell Therapy in a Population-Based Cohort of 3550 Patients with Incident Diffuse Large B-Cell Lymphoma (DLBCL) in Sweden

Karin Ekstroem Smedby, Sara Harrysson, MD, Sara Ekberg, Mats Jerkeman, MD PhD, Per-Ola Andersson, MD PhD, Gunilla Enblad, Sandra Eloranta

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-138737

Published: 2020

Journal Articles

Incidence of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Including CNS Relapse in a Population-Based Cohort of 4205 Patients in Sweden

Sara Harrysson, MD, Sandra Eloranta, Sara Ekberg, Gunilla Enblad, Mats Jerkeman, MD Professor, Sverker Hasselblom, Björn E Wahlin, MD PhD, Per-Ola Andersson, MD PhD, Karin E. Smedby, MD PhD

Blood (2019) 134 (Supplement_1): 399.

https://doi.org/10.1182/blood-2019-122014

Published: 2019

Journal Articles

Treatment Intensity, Timing of Relapse and Outcome of 713 Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in a Population-Based Setting in Sweden

Karin Ekstrom Ekstroem Smedby, Sara Ekberg, Sandra Eloranta, Gunilla Enblad, Mats Jerkeman, MD Professor, Per-Ola Andersson, MD PhD, Sara Harrysson, MD

Blood (2019) 134 (Supplement_1): 4111.

https://doi.org/10.1182/blood-2019-123785

Published: 2019

Journal Articles

Outcome and Determinants of Failure to Complete 6-8 Cycles of Primary R-CHOP Treatment for Reasons Unrelated to Progression Among Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Karin Ekstrom Smedby, MD PhD, Sara Harrysson, MD, Per-Ola Andersson, Gunilla Enblad, Sara Ekberg, Mats Jerkeman, Sandra Eloranta

Blood (2018) 132 (Supplement 1): 4200.

https://doi.org/10.1182/blood-2018-99-116343

Published: 2018

Journal Articles

Incidence and Outcome of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in a Population-Based Cohort of 3165 Patients in Sweden

Sara Harrysson, MD, Sandra Eloranta, Sara Ekberg, Gunilla Enblad, Mats Jerkeman, Sverker Hasselblom, Björn E Wahlin, Per-Ola Andersson, Karin E Smedby

Blood (2018) 132 (Supplement 1): 2975.

https://doi.org/10.1182/blood-2018-99-110672

Published: 2018

NARROW

Timing of Disease Progression and Impact on Survival in Mantle Cell Lymphoma: A Novel Illness-Death Model Study from the Swedish Mclcomplete Project

Survival in Mantle Cell Lymphoma Patients with a Second Primary Malignancy

An International Multicohort Study of Conditional Survival and Cause of Death after Achieving Event-Free Survival at 24 Months in Patients with Mantle Cell Lymphoma

Sars-Cov-2 Infection Does Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study

Risk Factors of Smoldering Multiple Myeloma: Results from the Screened Istopmm Study

Sars-Cov-2 Vaccinations Do Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study

Transient M-Proteins: Epidemiology, Causes, and the Impact of Mass Spectrometry: The Istopmm Study

Late Effects after Treatment in Mantle Cell Lymphoma: No Difference By Intensity of First-Line Regimens with or without Autologous Stem Cell Transplantation

Idelalisib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: First Results from the Nordic Lymphoma Group NLG-LBC-07 (ILIAD) Phase II Trial

Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - Data from the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase I Trial: Stopping Treatment in Molecular Remission Is Feasible

Evaluation of Eligibility for CAR-T Cell Therapy in a Population-Based Cohort of 3550 Patients with Incident Diffuse Large B-Cell Lymphoma (DLBCL) in Sweden

Incidence of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Including CNS Relapse in a Population-Based Cohort of 4205 Patients in Sweden

Treatment Intensity, Timing of Relapse and Outcome of 713 Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in a Population-Based Setting in Sweden

Outcome and Determinants of Failure to Complete 6-8 Cycles of Primary R-CHOP Treatment for Reasons Unrelated to Progression Among Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Incidence and Outcome of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in a Population-Based Cohort of 3165 Patients in Sweden

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only